Padmanabh P. Bhatt - 27 Jan 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
Sr. VP of IP, CSO
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
27 Jan 2025
Net transactions value
-$32,763
Form type
4
Filing time
29 Jan 2025, 17:04:45 UTC
Previous filing
04 Dec 2024
Next filing
05 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $76,187 +2,573 +25% $29.61 12,722 27 Jan 2025 Direct F1
transaction SUPN Common Stock Sale $101,942 -2,573 -20% $39.62 10,149 27 Jan 2025 Direct F2
transaction SUPN Common Stock Options Exercise $20,727 +700 +6.9% $29.61 10,849 28 Jan 2025 Direct
transaction SUPN Common Stock Sale $27,734 -700 -6.5% $39.62 10,149 28 Jan 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -2,573 -20% $0.000000 10,177 27 Jan 2025 Common Stock 2,573 $29.61 Direct F4
transaction SUPN Performance Share Units Award $0 +1,650 $0.000000 1,650 28 Jan 2025 Common Stock 1,650 $0.000000 Direct F5
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -700 -6.9% $0.000000 9,477 28 Jan 2025 Common Stock 700 $29.61 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes an aggregate of 470 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $39.67. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $39.63. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4 The option vested in four equal installments beginning on February 19, 2022.
F5 On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.